Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104455 · ClinicalTrials.gov registry record · Phase 1
Dose Response to Recombinant Factor VIIa When Administered for Bleed
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00104455 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 64 participants.
The verdict
NCT00104455, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
Interventions
- DRUG activated recombinant human factor VII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2004-06 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104455
The ClinicalTrials.gov registry entry for NCT00104455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which activated recombinant human factor VII is the first listed.
NCT00104455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104455 about?
NCT00104455 is a clinical study titled "Dose Response to Recombinant Factor VIIa When Administered for Bleed". This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
What is the current status of trial NCT00104455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2004-06. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00104455?
The interventions under investigation include: activated recombinant human factor VII (DRUG).
Who is sponsoring clinical trial NCT00104455?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.